Nicotine-blocking therapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
15
NCT07215923
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 31, 2025
Completion: Sep 30, 2026
Loading map...